BUSINESS
Stroke third leading cause of death in India, dementia is fastest growing neurological disorder
Stroke caused 699,000 deaths in India in 2019, accounting for 7.4 percent of the total deaths in the country.
BUSINESS
Bharat Biotech faces hitches in scramble to raise Covaxin output
Manufacturing complexity and testing requirements may be delaying the ramp up in Bharat Biotech’s capacity to produce the made-in-India COVID-19 vaccine Covaxin
BUSINESS
Oximeters, BP machines and 3 other devices to get cheaper as trade margins capped at 70%
The National Pharmaceutical Pricing Authority has capped trade margins at 70 percent for pulse oximeter, blood pressure monitoring machine, nebulizer, digital thermometer and glucometer. The revised prices come into effect from July 20
BUSINESS
Expect commercial supplies of Sputnik vaccine from Indian manufacturers by September: RDIF
"Manufactures have begun producing (Sputnik V) vaccine, Gamelya Institute already verified their quality. Some of the manufacturers are ready to produce and others are producing commercial batches," said Kirill Dmitriev, CEO of RDIF.
BUSINESS
Govt exempts customs duty on Amphotericin B, COVID test kits' raw materials
The move is expected to address the shortage and also reduce the prices of Amphotericin B injection, vital in the treatment of mucormycosis, better known as black fungus
BUSINESS
COVID-19 vaccine | Serum Institute inks pact with RDIF to make Sputnik V, to begin first batch production in September
Serum Institute and RDIF plan to produce over 300 million doses of the Sputnik V vaccine in India per year.
BUSINESS
Commercial rollout of Sputnik V vaccine is not put on hold, says Dr Reddy's
Dr Reddy's said there was a 'slight' delay in commercial rollout of Sputnik V vaccine. The delay is "due to dependency on imported consignments, and quality testing in India".
BUSINESS
How Nobel Hygiene, the Nashik-based diaper maker, carved a niche in a market dominated by MNCs
Nobel Hygiene has been able to grow over five-fold in the last five years maintaining a 35 percent CAGR and closed FY 21 with revenue close to Rs 600 crores.
BUSINESS
Committed to growth, reports on company sale are false: Granules management
"We would like to deny these messages as they are utterly false and malicious. The management continues to remain committed to the growth of the company,'' Granules statement said.
BUSINESS
Antiviral drug Molnupiravir helps mild COVID-19 patients recover faster: Hetero
Earlier, SARS CoV-2 RT-PCR negativity observed in Molnupiravir group compared standard of care at Day 5 was 77.35 percent vs 26.07 percent.
BUSINESS
Explained | Delta plus variants and what does INSACOG say about them
The labs dedicated to whole genome sequencing say the variants, which are mutations of the Delta strain first found in India, could be more infectious and cause severe COVID-19
BUSINESS
Ayush Ministry refutes study that linked Ayurvedic herb 'Giloy' to liver failure
Relating Giloy or TC to liver damage would be misleading and disastrous to the traditional medicine system of India as the herb has been used in Ayurveda since long, an Ayush Ministry statement said.
BUSINESS
Biological E enters into pact to buy Dynavax's adjuvant for use in COVID-19 subunit vaccine
The agreement includes doses for delivery in 2021, which were manufactured under the previously announced funding agreement between the Coalition for Epidemic Preparedness Innovations and Dynavax. India entered into an advance purchase deal with BE to buy 30 crore doses.
BUSINESS
Drug firms seek free export of Remdesivir as weak demand inflates inventories
Drug makers had ramped up their capacity to make Remdesivir amid acute scarcity during the second wave of the coronavirus pandemic, but demand has crashed in step with the steep fall in the number of new cases.
BUSINESS
Govt affidavit to SC estimates a severe slash in vaccine doses from 216 crore to 135 crore for August-December 2021
As manufacturers struggle to scale up production, the pace of vaccination drive is at risk of losing momentum once again; hospitals admit supply has been erratic lately
BUSINESS
Sputnik V vaccine: Panacea Biotec's Baddi unit gets license from DCGI to manufacture jabs
"The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli, Himachal Pradesh in India," Panacea told stock exchanges on July 5.
BUSINESS
Why Sputnik V vaccine rollout may not hit full capacity until August-September
Imports of the vaccine from Russia are delayed because of heavy orders from several countries and a likely diversion of supplies for local inoculation drives amid a spike in infections caused by the Delta variant of the coronavirus
BUSINESS
Johnson & Johnson says its single-shot COVID-19 vaccine offers durable protection against Delta, other variants
The data from Johnson & Johnson showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date.
BUSINESS
Dr Reddy's says expert panel sought Phase-3 data of Sputnik V in Russia to consider Sputnik Light
"The SEC observed that in view of the safety and immunogenicity data already generated by Dr Reddy’s in India on the first dose component of Sputnik V (in other words, Sputnik Light), there was no need for a separate Phase III trial of Sputnik Light in India," the company said.
BUSINESS
COVID vaccine | Zydus Cadila plans to roll out ZyCoV-D in 45-60 days following regulatory approvals
Zydus said it can produce up 4-5 lakh doses at its old facilites, and expects to produce 1 crore doses monthly from mid of August, once the new manufacturing facility comes on board likely from the end of July.
BUSINESS
Supreme Court sets aside Indoco’s request to lift injunction on launch of generic apixaban
Apex court dismisses Indoco’s petition to lift the stay on producing copycat versions of Bristol Myers Squibb’s bestselling anticoagulant medication
BUSINESS
Zydus’ COVID-19 vaccine shows 66.6% efficacy in Phase-3 interim analysis, company files for emergency use
No moderate case of COVID-19 disease was observed in the vaccine arm post administration of the third dose suggesting 100% efficacy for moderate disease. No severe cases or deaths due to COVID-19 occurred in the vaccine arm after administration of the second dose of the vaccine.
BUSINESS
Here is what five experts are saying on 'mix and match' of COVID-19 vaccines
There are some studies mostly conducted in Europe that show that if you use Oxford-AstraZeneca vaccine followed by Pfizer-BioNTech vaccine - that there is increase in reactogencity and the antibody response is little higher- which is good, says one of the experts.
BUSINESS
Bharat Biotech says hasn't got advance payment nor supplied jabs to Brazil
Bharat Biotech was responding to reports in media about the allegations of graft surrounding the $324-million Covaxin contract signed by Brazil, which has since been suspended by that country.
